Quick Answer
VOLITIONRX LTD reported Total Revenue of $1.73 million for fiscal year 2025.
VOLITIONRX LTD — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.73M +40.0% |
$1.23M +59.1% |
$775.3K +153.0% |
$306.4K +240.3% |
$90.0K +570.3% |
$13.4K -21.4% |
| Net Income | -$23.36M +13.4% |
-$26.97M +24.4% |
-$35.68M -16.6% |
-$30.60M -13.4% |
-$26.99M -32.3% |
-$20.40M -26.7% |
| Diluted EPS | — | -$0.31 +38.0% |
-$0.50 | — | — | — |
| Total Assets | $6.90M -26.6% |
$9.40M -66.4% |
$27.95M +52.8% |
$18.30M -33.4% |
$27.49M +5.1% |
$26.15M +22.8% |
| Cash and Equivalents | — | — | $20.73M +90.8% |
$10.87M -47.2% |
$20.58M +5.8% |
$19.44M +14.6% |
| Long-Term Debt | $5.82M +47.2% |
$3.95M +9.0% |
$3.62M +30.4% |
$2.78M +22.4% |
$2.27M -12.9% |
$2.61M +18.7% |
| Stockholders Equity | -$34.25M -37.5% |
-$24.91M -219.2% |
-$7.80M -203.0% |
-$2.57M -114.5% |
$17.72M +8.8% |
$16.29M +14.8% |
| R&D Expense | $10.08M -30.0% |
$14.41M -26.3% |
$19.55M +27.5% |
$15.33M +17.7% |
$13.02M -10.4% |
$14.53M +40.2% |
| Operating Income | -$21.74M +19.6% |
-$27.02M +24.9% |
-$35.99M -13.2% |
-$31.78M -12.2% |
-$28.33M -33.3% |
-$21.25M -32.4% |
| Shares Outstanding | 125.78M +30.9% |
96.10M +17.3% |
81.90M +41.5% |
57.87M +7.6% |
53.77M +10.6% |
48.61M +18.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $627.3K | +32.2% | +54.2% |
| Net Income | September 30, 2025 | -$5.38M | +7.6% | +14.4% |
| Diluted EPS | September 30, 2025 | -$0.05 | +28.6% | +16.7% |
| Total Assets | September 30, 2025 | $6.45M | -49.1% | -25.9% |
| Cash and Equivalents | March 31, 2024 | $11.77M | +17.6% | -43.2% |
| Long-Term Debt | September 30, 2025 | $5.57M | +45.0% | -3.6% |
| Stockholders Equity | September 30, 2025 | -$34.64M | -61.1% | -8.9% |
| R&D Expense | September 30, 2025 | $2.29M | -34.2% | -16.0% |
| Operating Income | September 30, 2025 | -$5.10M | +13.1% | +19.0% |
| Shares Outstanding | September 30, 2025 | 109.62M | +18.6% | +5.4% |
- VOLITIONRX LTD reported Total Revenue of $1.73 million for fiscal year 2025.
- VOLITIONRX LTD showed an increase of +40.0% in Total Revenue compared to the prior fiscal year.
- VOLITIONRX LTD reported Net Income of -$23.36 million for fiscal year 2025.
- VOLITIONRX LTD showed an increase of +13.4% in Net Income compared to the prior fiscal year.
- VOLITIONRX LTD reported Diluted EPS of $0.31 per share (loss) for fiscal year 2024.
- VOLITIONRX LTD showed an increase of +38.0% in Diluted EPS compared to the prior fiscal year.
- VOLITIONRX LTD reported Total Assets of $6.90 million for fiscal year 2025.
- VOLITIONRX LTD showed a decrease of -26.6% in Total Assets compared to the prior fiscal year.
- VOLITIONRX LTD reported Cash and Equivalents of $20.73 million for fiscal year 2023.
- VOLITIONRX LTD showed an increase of +90.8% in Cash and Equivalents compared to the prior fiscal year.
- VOLITIONRX LTD reported Long-Term Debt of $5.82 million for fiscal year 2025.
- VOLITIONRX LTD showed an increase of +47.2% in Long-Term Debt compared to the prior fiscal year.
- VOLITIONRX LTD reported Stockholders Equity of -$34.25 million for fiscal year 2025.
- VOLITIONRX LTD showed a decrease of -37.5% in Stockholders Equity compared to the prior fiscal year.
- VOLITIONRX LTD reported R&D Expense of $10.08 million for fiscal year 2025.
- VOLITIONRX LTD showed a decrease of -30.0% in R&D Expense compared to the prior fiscal year.
- VOLITIONRX LTD reported Operating Income of -$21.74 million for fiscal year 2025.
- VOLITIONRX LTD showed an increase of +19.6% in Operating Income compared to the prior fiscal year.
- VOLITIONRX LTD reported Shares Outstanding of 125.78 million shares for fiscal year 2025.
- VOLITIONRX LTD showed an increase of +30.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: